Case 1:14-cv-01332-UNA Document 4 Filed 10/21/14 Page 1 of 1 PageID #: 148
`
`A0 120 Rev. 08/10
`
`TRADEMARK
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`To
`'
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`District of Delaware
`on the following
`
`I:] Trademarks or
`
`IZPatents.
`
`( E] the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`DATE FILED
`10/21/2014
`
`U.S. DISTRICT COURT
`
`District of Delaware
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`WOCKHARDT BIO LTD., WOCKHARDT LTD., and WOCKHARDT USA, LLC
`
`DEFENDANT
`
`——
`
`DATE INCLUDED
`
`In the above——entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`CI Amendment
`
`[:I Answer
`
`I] Cross Bill
`
`[3 Other Pleading
`
`HOLDER or PATENT OR TRADEMARK
`%’;T¥R(fD1;:’:ATE:I:
`Tfiggmfio
`_——
`——
`——
`——
`——
`
`
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`
`
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3———Upon termination of action, mail this copy to Director
`Copy 2——Upon filing document adding patent(s), mail this copy to Director Copy 4~—Case file copy
`
`AGILA ET AL - EXHIBIT 1019
`
`0001
`
`0001
`
`AGILA ET AL - EXHIBIT 1019
`
`

`
`Case 1:14—cv-01117—GMS Document 10 Filed 10/03/14 Page 1 of 3 PagelD #: 151
`
`Case 1:14—cv-01117—GMS Document 4 Filed 09/02/14 Page 1 of 1 PagelD #: 144
`A0 I20 Rev. 08/10
`
` REPORT ON THE
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`PO. Box 1450
`
`Alexandria, VA 22313-1450
`
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`District of Delaware
`on the following
`
`El Trademarks or
`
`[Z Patents.
`
`( I] the patent action involves 35 U.S.C. §292.):
`
`DOCKET NO.
`
`PLAINTIFF
`
`DATE FILED
`9/2/2014
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`District of Delaware
`
`CEPHALON, INC.
`
`NANG KUANG PHARMACEUTICAL CO., LTD. and
`CANDA NK-1, LLC
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`5/21/2013
`
`5/7/2013
`
`12/17/2013
`
`7/29/2014
`
`DATE INCLUDED
`
`INCLUDED BY
`
`[J Amendment
`
`C] Answer
`
`1:] Cross Bill
`
`C] Other Pleadin
`
`HOLDER OF PATENT OR TRADEMARK
`
`
`
`In the above—entitled case, the following decision has been rendered orjudgement issued:
`DECISION/JUDGEMENT
`
`CLERK United
`844
`
`tate Dsrict Court
`King Street. Unit 18
`. U
`
`Copy l——-—Upon initiation of action, mail this copy to Direc r
`Copy 3—Upon termination of action. mail this copy to Director
`Copy 2-—Upon filing document adding patent(s), mail this copy to Director
`Copy 4——Case file copy
`
`0002
`
`0002
`
`

`
`Case 1:13—cv—02095—GMS Document 29 Filed 09/18/14 Page 1 of 1 Page|D #: 454
`
`A0 120 Rev. 08/10
`
`TO.
`'
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`TRADEMARK
`
`Alexandria, VA 22313-1450
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`for the District of Delaware
`on the following
`
`I] Trademarks or
`
`lZPatents.
`
`( El the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`13-2095—GMS
`PLAINTIFF
`
`
`
`
`
`
`DATE FILED
`9/18/2014
`
`U.S. DISTRICT COURT
`for the District of Delaware
`
`DEFENDANT
`ACCORD HEALTHCARE, INC. and INTAS
`
`
`
`
`
`
`CEPHALON, INC.
`
`PHARMACEUTICALS LTD.
`
`
`
`
`
`
`
`——
`——
`
`
`
`In the above—entitled case, the following patent(s)/ trademaIk(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENT OR
`
`M Amendment
`DATE OF PATENT
`
`E] Answer
`
`[:1 Cross Bill
`
`D Other Pleading
`
`WW
`
`1 8,791,270
`
`7/29/2014
`
`CEPHALON, INC.
`
`
`
`———_
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`
` (BY) DEPUTY CLERK
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4——Case file copy
`
`0003
`
`0003
`
`

`
`Case 1:14-cv-01116-UNA Document 4 Filed 09/02/14 Page 1 of 1 Page|D #: 149
`A0 120 Rev. 08/10
`
`TRADEMARK
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Coufl
`District of Delaware
`on the following
`
`I:l Trademarks or
`
`[ZPatents.
`
`( [:I the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`PLAINTIFF
`
`DATE FILED
`9/2/2014
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`District of Delaware
`
`
`
`CEPHALON, INC.
`
`SAGENT PHARMACEUTICALS, INC. and
`SAGENT AGILA LLC
`
`
`
`
`
`
`
`
`
`
`
`
`‘—
`
`
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`[I Answer
`
`B Cross Bill
`
`[:1 Other Pleading
`
`I
`
`[] Amendment
`PATENT OR
`DATE OF PATENT
`TRADEMARK NO.
`OR TRADEMARK
`HOLDER OF PATENT OR TRADEMARK
`———
`——
`——
`-—
`
`——
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy l—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—-Case file copy
`
`0004
`
`
`
`0004
`
`

`
`Case 1:14-cv—00671-UNA Document 5 Filed 05/27/14 Page 1 of 1 Page|D #: 112
`A0 120 Rev. 08/10
`
`TRADEMARK
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`District of Delaware
`on the following
`
`E] Trademarks or
`
`[2IPatents.
`
`( E] the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`
`
`DATE FILED
`5/27/2014
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`District of Delaware
`
`BRECKENRIDGE PHARMACEUTICAL, INC.
`and NATCO PHARMA LTD.
`
`PATENT OR
`TRADEMARK NO.
`
`
`
`
`
`
`DATE OF PATENT
`OR TRADEMARK
`
`
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`I:] Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`E] Answer
`
`[I Cross Bill
`
`[I Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`
`
`——
`
`
`
`——
`——
`——
`—_
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
` ——
` (BY) DEPUTY CLERK
`
`DATE
`
`Copy l—Upon initiation of action, mail this copy to Director Copy 3»—Upon termination of action, mail this copy to Director
`Copy 2—Up0n filing document adding patent(s), mail this copy to Director Copy 4—-—Case file copy
`
`0005
`
`0005
`
`

`
`Case 1:13—cv-02095-GMSI Document 15 Filed 04/09/14 Page 1 of 1 PagelD #: 224
`
`TRADEMARK
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`for the District Of Delaware
`on the following
`I] Trademarks or
`MP2itents.
`( I] the patent action involves 35 U.S.C. § 292.):
`
`13-2095-GMS
`PLAINTIFF
`
`CEPHALON, INC.
`
`12/26/2013
`
`for the District of Delaware
`
`DEFENDANT
`ACCORD HEALTHCARE, INC. and INTAS
`PHARMACEUTICALS LTD.
`
`
`
`1 8,445,524
`
`5/21/2013
`
`CEPHALON, INC.
`
`2 8,436,190
`
`5/7/2013
`
`CEPHALON, INC.
`
`——
`_—
`——
`
`In the above—entit1ed case, the following patent(s)/ trademark(s) have been included:
`
`DATE IN U
`Sig/£)g?4
`
`
`
`INCLUDED BY
`
`M Amendment
`
`E] Answer
`
`B Cross Bill
`
`C] Other Pleading
`
`
`
`1 8,609,863
`
`2
`
`12/17/2013
`
`CEPHALON, INC.
`
`DECISION/JUDGEMENT
`
`(BY) DEPUTY CLERK
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2——Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0006
`
`0006
`
`

`
`Case 1:14-cv-00333-UNA Document 4 Filed 03/14/14 Page 1 of 1 PagelD #: 45
`A0 120 Rev. 08/10
`
`T0:
`
`Mail Stop 3
`Director of the U.S. Patent and Trademark Office
`P.0. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`for the District of Delaware
`on the following
`
`El Trademarks or
`
`lZPatents.
`
`( [I the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`PLAINTIFF
`
`DATE FILED
`3/14/2014
`
`
`
`U.S. DISTRICT COURT
`for the District of Delaware
`
`
`
`DEFENDANT
`
`
`
`
`CEPHALON, INC.
`
`PATENT OR
`
`TRADEMARK
`
`DATE OF PATENT
`
`SUN PHARMA GLOBAL FZE, SUN PHARMACEUTICAL
`INDUSTRIES LTD., and SUN PHARMACEUTICAL
`INDUSTRIES, INC.
`
`
`
`
`
`
`
`
`1 US 8,609,863 B2
`
`12/17/2013
`
`Cephalon, Inc.
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`DATE INCLUDED
`
`[:I Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`1:] Answer
`
`I] Cross Bill
`
`El Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`PATENT OR
`TRADEMARK NO.
`
`In the above—£ntitled case, the following decision has been rendered or judgement issued:
`DECISION/IUDGEMENT
`
`(BY) DEPUTY CLERK
`
`Copy l—I7pon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2——Upon filing document adding patent(s), mail this copy to Director Copy 4——Case file copy
`
`0007
`
`0007
`
`

`
`Case 1:14-cv-00334-UNA Document 4 Filed 03/14/14 Page 1 of 1 PageID #: 44
`
`A0 120 Rev. 08/10
`
` TO
`
`'
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`for the District of Delaware
`on the following
`
`[I Trademarks or
`
`I] Patents.
`
`(
`
`|:] the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`DATE FILED
`3/14/2014
`
`U.S. DISTRICT COURT
`for the District of Delaware
`
`DEFENDANT
`
`DR. REDDY’S LABORATORIES, LTD. and DR.
`REDDY’S LABORATORIES, INC.
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`12/17/2013
`
`Cephalon, Inc.
`
`
`
`El Answer
`
`I: Cross Bill
`
`C] Other Pleading
`
` INCLUDED BY
`DATE INCLUDED
`El Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`PATENT OR
`TRADEMARK NO.
`
`HOLDER OF PATENT OR TRADEMARK
`(BY) DEPUTY CLERK
`
`
`
`
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/IUDGEMENT
`
`Copy l—Upon initiation of action, mail this copy to Director Copy 3~—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4-——C-ase file copy
`
`0008
`
`0008
`
`

`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`13/719,379
`
`ISSUE DATE
`
`12/17/2013
`
`46347
`
`7590
`
`11/26/2013
`
`WOODCOCK WASHBURN LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`8609863
`
`CEPH-4457/CP391B US
`
`6187
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above—identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above—identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto. gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(S) (Please see PAIR WEB site http://pair.uspto. gov for additional applicants):
`
`Jason Edward Brittain, El Cajon, CA;
`Joe Craig Franklin, Tulsa, OK;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about why the USA is the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`IR103 (Rev. 10/09)
`
`0009
`
`0009
`
`

`
`Receipt date: 06/03/2013
`
`t37t93'I/"9 ~ GAL}: 1617
`
`Substitute for 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BYAPPLICANT
`
`(use as many sheets as necessary)
`
`_
`_
`Application Number
`
`Complete if Known
`
`13/719,379
`
`Art Unit
`
`1 61 7
`
`Soroush, Ali
`CEPH-4457 I <>P391B U8
`
`
`
`U. S. PATENT APPLICATION DOCUMENTS
`
`Examiner
`
`Cite
`
`.
`
`.
`
`Application Number
`M 13/719,409
`
`Fling Date
`
`MM_DD_YYYY
`12-19-2012
`
`Name ofPatentee orApplicantofCited Document
`Cephalon, Inc.
`
`.
`
`.
`
`U. S. PUBLICATION AND PATENT DOCUMENTS
`
`CiIargi(§-IQ-fiI)Ie?P II?IIe
`to OCID,IrIT§3CSnt,
`0-
`
`Docunfient Num_ber
`Number — Kind Code (If known)
`
`Pg-I;:IaI(r:1ItaII30arIt<=f)r
`MM_DD_YYYY
`
`Name of Patentee or Applicant of Cited Document
`
`3
`
`brfttain; Jasgn Edward; at aI
`
`I
`
`1
`
`15/,/,z?,g,§i5
`
`113
`
`8,436,190
`
`05-07-2013
`
`Brittain, J.E. et al.
`
`NON PATENT LITERATURE DOCUMENTS
`
`Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial,
`symposium, catalog, etc.), date, page(s), Volume-issue Number(s), publisher, city and/or country where published.
`
`Sciences, April 1998, 87(4), 491-495
`
`Teagarden et ai., “Practical aspects of lyophilization using non-aqueous co-solvent
`systems,” European Journal of Pharmaceutical Sciences, March 2002, 15(2), 115-133
`
`Wittaya-Areekul et ai., “Freeze-drying of tert-butyl alcohol/water cosolvent systems: Effects
`of formulation and process variables on residual solvents,” Journal of Pharmaceutical
`
` Examiner
`1OW?’
`
`Date
`
`_
`
`,1
`
`,
`
`0010
`
`0010
`
`

`
`Receipt date: 01/28/2013
`
`‘$719379 ~ GAL}: 1617
`
`Substitute for 1449/PTO
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`(use as many sheets as necessary)
`
`Complete if Known
`13/719379
`
`Jason Edward Brittain
`1629
`Not Yet Assigned
`CEPH-4457/CP391B US
`
`U. S. PUBLICATION AND PATENT DOCUMENTS
`Publication or
`Document Number
`
`ME/|r_%n$_|Z\)(:$$Y
`03-09-1993
`04-20-1993
`
`Name OfPatentee orApplicantOfCited Document
`Hsu etal.
`Sauerbier et al.
`
`
`
`Number_Kind Code (ifknown)
`3 5,192,743
`26
`5,204,335
`
`E:
`
`27
`
`28
`
`29
`
`5,227,373
`
`5,227,374
`
`5,268,368
`
`6,077,650
`6,090,365
`6,271,253
`6,360,210
`6,492,390
`6,545,034
`6,569,402
`6,573,292
`3 6,613,927
`
`07-13-1993
`
`Alexander et al.
`
`07-13-1993
`
`Alexander et al.
`
`12-07-1993
`
`Palepu
`
`05-09-1995
`
`Alexander et al.
`
`05-23-1995
`
`Palepu et al.
`
`05-12-1998
`
`Wichert et al.
`
`06-23-1998
`
`Teagarden et al.
`
`07-07-1998
`
`Anderson et al.
`
`09-21-1999
`
`Wechter et al.
`
`10-26-1999
`03-07-2000
`06-20-2000
`07-16-2000
`08-07-2001
`04-30-2002
`12-12-2002
`04-06-2003
`05-27-2003
`06-03-2003
`09-02-2003
`
`Marek et al.
`-lVl-as-fen-rer Carter et aI
`Ma'sfe-rre1-
`Ca.-Cc, at 31
`Kaminski et al.
`-Mas'l‘er1-er“
`Carter et aI.
`Desimone et al.
`-Ma-9fe-r+e-r-
`Carter 6-, 31,
`Carson et al.
`Cheesman et al.
`Nardella
`Kwok
`
`Examiner
`
`Sinature
`
`Considered
`
`Date
`
`0011
`
`0011
`
`

`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.goV
`
`APPLICATION NO.
`
`F ING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONF {MATION NO.
`
`13/719,379
`
`12/19/2012
`
`Jason Edward Brittain
`
`CEPH—4457/CP391B US
`
`6187
`
`46347
`7590
`11/18/2013
`WOODCOCK WASHBURN LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH S TRET
`
`S0R0USH,AL1
`
`1617
`
`11/18/2013
`
`ELECTRONIC
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`Notice of the Office communication was sent electronically on aboVe—indicated "Notification Date" to the
`following e—mail address(es):
`eofficemonitor @ w00dcock.c0m
`
`PTOL—90A (Rev. 04/07)
`
`0012
`
`0012
`
`

`
`UNITED STATES DEPARTMENT OF COMMERCE
`
`U.S. Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`
`Alexandria, Virginia 22313-1450
`
`APPLICATION N0.l
`CONTROL NO.
`
`FILING DATE
`
`FIRST NAMED INVENTORI
`PATENT IN REEXAMINATION
`
`ATTORNEY DOCKET NO.
`
`13/719,379
`
`19 December, 2012
`
`BRITTAIN ET AL.
`
`CEPH—4457/CP391B US
`
`
`
`WOODCOCK WASHBURN LLP
`
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`EXAMINER
`
`ART UN”
`
`PAPER
`
`OPIM
`
`A-82087
`
`DATE MAILED:
`
`Please find below and/or attached an Office communication concerning this application or
`proceeding.
`
`The attached addendum forms part of the previously mailed PTOL-85 (Notice of Allowance and Fees Due). This addendum does
`NOT change the time period set in the PTOL-85 for payment of the issue fee.
`
`ANY QUESTIONS REGARDING THIS COMMUNICATION SHOULD BE DIRECTED TO THE OFFICE OF PATENT LEGAL
`ADMINISTRATION AT (571) 272-7701.
`
`Commissioner for Patents
`
`PTO-90C (Rev.04-03)
`
`0013
`
`0013
`
`

`
`Notices of Allowance and Fee(s) Due mailed between October 1, 2013 and
`December 31, 2013
`
`(Addendum to PTOL—85)
`
`If the “Notice of Allowance and Fee(s) Due” has a mailing date on or after October 1, 2013 and before
`January 1, 2014, the following information is applicable to this application.
`
`If the issue fee is being timely paid on or after January 1, 2014, the amount due is the issue fee and
`publication fee in effect January 1, 2014. On January 1, 2014, the issue fees set forth in 37 CFR 1.18
`decrease significantly and the publication fee set forth in 37 CFR l.l8(d)(l) decreases to $0.
`
`If an issue fee or publication fee has been previously paid in this application, applicant is not entitled to a
`refund of the difference between the amount paid and the amount in effect on January 1, 2014.
`
`0014
`
`0014
`
`

`
`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or 1 (571)-273-2885
`
`through 5 should be completed where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1
`appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`in icated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for
`maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any Change Ofaddress)
`
`46347
`
`7590
`
`10/02/2013
`LLP
`
`CIRA CENTRE’ 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`Note: A certificate of mailin can only be used for domestic mailings of the
`Fee(s) Transmittal. This certi icate cannot be used for any other accompanying
`fiapers. Each additional paper, such as an assignment or formal drawing, must
`ave its own certificate of mailing or transmission.
`
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`S(ti2(1ites Poistal Stfirvilc/E:
`suffiScé%1]tEpg]sEt]a:ge(f((i)r first glass mailbin an Envelope
`a
`resse
`to
`e
`a1
`top
`a
`ress a ove, or
`e1ng
`acs1m1 e
`transmitted to the USPTO (571) 273-2885, on the date indicated below.
`V
`I
`‘D°P°“‘°”“‘“°>
`(Signature)
`
`(Date)
`
`APPLICATION NO.
`
`FILING DATE
`
`F {ST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`Jason Edward Brittain
`12/19/2012
`13/719,379
`TITLE OF INVENTION: BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`CEPH—4457/CP391B US
`
`6187
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE
`
`PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$1780
`
`$0
`
`$0
`
`$1780
`
`01/02/2014
`
`SOROUSH, ALI
`
`1617
`
`548—304700
`
`1. Change of correspondence address or indication of "Fee Address" (37
`CFR 1.363).
`
`3 Chan e of correspondence address (or Change of Correspondence
`Address orm PTO/SB/ 122) attached.
`
`3 "Fee Address" indication (or "Fee Address" Indication form
`PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer
`Vumber is required.
`
`2. For printing on the patent front page, list
`(1) the names of up to 3 registered patent attorneys
`or agents OR, alternatively,
`(2) the name of a single firm (having as a member a
`registered attorney or agent) and the names of up to
`2 registered patent attorneys or agents. If no name is
`listed, no name will be printed.
`
`
`
`1 Woodcock Washburn LLP
`
`2
`
`3
`
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
`If an assignee is identified below, the document has been filed for
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent.
`recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAME OF ASSIGNEE
`(B) RESIDENCE: (CITY and STATE OR COUNTRY)
`
`Cephalon, Inc.
`
`Frazer, Pennsylvania
`
`Please check the appropriate assignee category or categories (will not be printed on the patent) :
`
`'3 Individual @ Corporation or other private group entity '3 Government
`
`4a. The following fee(s) are submitted:
`E Issue Fee
`
`4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)
`3 A check is enclosed.
`
`3 Publication Fee (No small entity discount permitted)
`3 Advance Order — # of Copies
`
`3 Payment by credit card. Form PTO—2038 is attached.
`3 The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any
`overpayment, to Deposit Account Number
`2 3 31 )5! )
`(enclose an extra copy of this form).
`
`PTOL—85 (Rev. 02/11)
`
`Page 2 of 4
`
`0015
`
`0015
`
`

`
`5. Change in Entity Status (from status indicated above)
`3 Applicant certifying micro entity status. See 37 CFR 1.29
`
`3 Applicant asserting small entity status. See 37 CFR 1.27
`
`3 Applicant changing to regular undiscounted fee status.
`
`NOTE: Absent a valid certification of Micro Entity Status (see form PTO/SB/ 15A and 15B), issue
`fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
`NOTE: If the application was previously under micro entity status, checking this box will be taken
`to be a notification of loss of entitlement to micro entity status.
`NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro
`entity status, as applicable.
`
`NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in
`interest as shown by the records of the United States Patent and Trademark Office.
`
`Authorized Signature
`
`/Stephanie A. Lodise/
`
`Date
`
`November 5, 2013
`
`Typed or printed name
`
`51430
`Registration No_
`Stephanie A. Lodise
`This collection of information is required by 37 CFR 1.311. The information is re uired to obtain or retain a benefit by the public which is to file (and by the USPTO to process)
`an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. T is collection is estimated to take 12 minutes to complete, including gathering, preparing, and
`submitting the completed application form to the USPTO. Time will v
`de endin upon the individual case. Any comments on the amount of time you require to complete
`this form and/or su gestions for reducing this burden, should be sent to
`e Chief In ormation Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O.
`Box 1450, Alexan ria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450,
`Alexandria, Virginia 223 13- 1450.
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`PTOL-85 (Rev. 02/11) Approved for use through 08/31/2013.
`
`OMB 0651-0033
`
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`Page 3 of 4
`
`0016
`
`0016
`
`

`
`Electronic Patent Application Fee Transmittal
`
`Title of Invention:
`
`BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`First Named Inventor/Applicant Name:
`
`Jason Edward Brittain
`
`Attorney Docket Number:
`
`CEPH—4457/CP391 B US
`
`Utility under 35 USC111(a) Filing Fees
`
`Description
`
`Fee Code
`
`Quantity
`
`Sub-Total in
`
`USD($)
`
`Basic Filing:
`
`Miscellaneous-Filing:
`
`Patent-Appeals-and-Interference:
`
`Post-AlIowance-and-Post-Issuance:
`
`UtilityAppl Issue Fee
`
`1501
`
`1780
`
`1780
`
`0017
`
`0017
`
`

`
`Miscellaneous:
`
` S“:-S1-;(t$a)| in
`
`Total in USD (S)
`
`0018
`
`0018
`
`

`
`Electronic Acknowledgement Receipt
`
`m—
`
`Title of Invention:
`
`BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`I
`
`Payment information:
`
`yes—
`Submitted with Payment
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)
`
`—Auth°“zedUser
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)
`
`0019
`
`0019
`
`

`
`Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)
`
`FHeLBfing:
`
`Document
`
`Information:
`
`Information:
`
`.
`
`.
`
`File Size(Bytes)/
`
`Multi
`
`Pages
`
`Issue Fee Payment (PTO-85B)
`
`Issue_fee_transmitta|.PDF
`
`1 12286
`
`d9l 687d6be8949529Ce93463cae58e6bc9d
`cfb6e
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`0fdaee13caed625061ad7161f9c7602481c4
`(:1 d
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`lfa new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`lfa timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`lfa new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and ofthe International Filing Date (Form PCT/R0/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`0020
`
`0020
`
`

`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`NOTICE OF ALLOWANCE AND FEE(S) DUE
`
`WOODCOCK WASHBURN LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`SOROUSH, ALI
`
`1617
`
`DATE MAILED: 10/02/2013
`
`Jason Edward Brittain
`12/19/2012
`13/719,379
`TITLE OF INVENTION: BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`CEPH—4457/CP391B US
`
`6187
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE
`
`PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$1780
`
`$0
`
`$0
`
`$1780
`
`01/02/2014
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY PERIOD CANNOT BE EXTENDED.
`SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW
`DUE.
`
`HOW TO REPLY TO THIS NOTICE:
`
`I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify Whether entitlement to that
`entity status still applies.
`
`If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.
`
`If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled
`"Change in Entity Status (from status indicated above)".
`
`For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity
`fees.
`
`II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office
`(USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b"
`of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a
`request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing
`the paper as an equivalent of Part B.
`
`III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to
`Mail Stop ISSUE FEE unless advised to the contrary.
`
`IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of
`maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.
`
`PTOL—85 (Rev. 02/11)
`
`Page 1 of 4
`
`0021
`
`0021
`
`

`
`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or 1 (571)-273-2885
`
`through 5 should be completed where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1
`appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`in icated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for
`maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any Change Ofaddress)
`
`46347
`
`7590
`
`10/02/2013
`LLP
`
`CIRA CENTRE’ 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`Note: A certificate of mailin can only be used for domestic mailings of the
`Fee(s) Transmittal. Th